Полиморфизм гена NAT2 в риске развития туберкулёза с множественной лекарственной устойчивостью при ВИЧ-инфекции
https://doi.org/10.37489/2588-0527-2020-2-12-13
About the Authors
Н. МальцеваRussian Federation
И. Викторова
Russian Federation
О. Казанцева
Russian Federation
А. Ханин
Russian Federation
References
1. Conaty SJ, Hayward AC, Story A et al. Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. Epidemiol. Infect. 2004;132(6):1099-1108. DOI: 10.1017/S0950268804002869.
2. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med. 1995;332(5):336-7. DOI: 10.1056/NEJM199502023320518.
3. Van Oosterhout JJ, Dzinjalamala FK, Dimba A et al. Pharmacokinetics of antituberculosis drugs in HIV-positive and HIV-negative adults in Malawi. Antimicrob Agents Chemother. 2015;59(10):6175-80. DOI: 10.1128/AAC.01193-15.
4. Mthiyane T, Millard J, Adamson J et al. N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment. Antimicrob Agents Chemother. 2020;64(4):e02376-19. DOI: 10.1128/AAC.02376-19.
5. Federal clinical guidelines for the diagnosis and treatment of tuberculosis in patients with HIV infection, 2015. (In Russ). http://roftb.ru/netcat_files/doks2016/rec2016.pdf
Review
For citations:
, , , . Pharmacogenetics and Pharmacogenomics. 2020;(2):12-13. (In Russ.) https://doi.org/10.37489/2588-0527-2020-2-12-13